Xilio Therapeutics Investor Relations Material

Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm focusing on discovering and developing tumor-activated immuno-oncology therapies. It focuses on creating treatments that are activated in the tumor environment, aiming to enhance the efficacy of immuno-oncology treatments while minimizing side effects. The company's portfolio includes a checkpoint inhibitor program with XTX101, an anti-CTLA-4 monoclonal antibody, alongside cytokine programs featuring XTX202 (a tumor-activated IL-2) and XTX301 (an engineered IL-12 molecule). The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.